July 26, 2018

Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update

Quarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the first quarter 2018 Submission of local coverage determination reconsideration request to the durable medical equipment Medicare administrative contractors following June CMS announcement of new payment rules for… Read More
learn more
July 19, 2018

Novocure Announces 13 Presentations at American Society for Radiation Oncology 2018 Annual Meeting

The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference Highlights include an analysis of the RTOG RPA scores in Novocure’s EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma and the first presentation of an analysis of the correlation… Read More
learn more
July 17, 2018

Scientific Track Dedicated to Tumor Treating Fields at 40th International Conference of the IEEE Engineering in Medicine and Biology Society

The IEEE Engineering in Medicine and Biology Society’s 40th International Conference is the first conference in which a scientific track will be devoted to Tumor Treating Fields, increasing the awareness of Novocure’s proprietary cancer therapy among the scientific community The conference will feature seven oral presentations on Tumor… Read More
learn more
July 2, 2018

Novocure Appoints Pritesh Shah as Chief Commercial Officer

With extensive experience in oncology, Pritesh Shah will be responsible for Novocure’s commercial strategy worldwide ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Pritesh Shah has been appointed as Novocure’s Chief Commercial Officer, reporting to Novocure’s Chief Executive Officer Asaf Danziger. In this role, Mr. Shah will… Read More
learn more
July 2, 2018

Novocure to Report Second Quarter 2018 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2018 on Thursday, July 26, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and… Read More
learn more
June 4, 2018

Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018

INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) will present today for the first time the design of its phase 3 pivotal trial of Tumor Treating Fields combined with… Read More
learn more
May 31, 2018

Novocure Announces Changes to Its Board of Directors

Former Medivation CEO, Dr. David T. Hung, elected to board of directors Former Avon CEO, Sherilyn D. McCoy, elected to board of directors Gert Lennart Perlhagen retiring after 15 years of service ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced changes to… Read More
learn more
April 26, 2018

Novocure Reports First Quarter 2018 Financial Results and Provides Company Update

2,009 active patients at March 31, 2018, an increase of 59 percent versus March 31, 2017 Delivered quarterly net revenues of $52.1 million, representing 49 percent growth versus the first quarter 2017 NCCN guidelines updated to recommend Optune in combination with temozolomide as a category… Read More
learn more
April 17, 2018

Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma

Final STELLAR data exceeded the results of the interim analysis for all efficacy endpoints Novocure plans to submit a Humanitarian Device Exemption application to the FDA for approval ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today positive top-line results from its STELLAR phase 2… Read More
learn more
April 13, 2018

Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting

Data support utility of Tumor Treating Fields in a variety of solid tumors A total of 35 presentations on the application of Tumor Treating Fields in seven cancer types will be presented ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that new data on… Read More
learn more